PBE
Invesco Biotechnology & Genome ETF
The Invesco Dynamic Biotechnology & Genome Portfolio ETF tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 280.3 M
ASSETS UNDER MGMT
58 bp
EXPENSES
Fund Basics
| Inception date | Jun 23, 2005 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| VERTEX PHARMACEUTICALS INC | 5.0 % |
| BIOGEN IDEC INC | 5.0 % |
| AMGEN INC | 4.9 % |
| ROYALTY PHARMA PLC CLASS A | 4.8 % |
| REGENERON PHARMACEUTICALS | 4.7 % |
| ALNYLAM PHARMACEUTICALS INC | 4.6 % |
| UNITED THERAPEUTICS CORP | 4.5 % |
| GILEAD SCIENCES INC | 4.5 % |
| CAREDX, INC. | 3.2 % |
| VERACYTE INC | 3.2 % |
Constituent Breakdown
| Number of holdings | 33 |
| Herfindahl-Hirschman Index | 355 |
| Wgt avg mkt cap (mns) | $34,350 |
| Large cap (>$10bn) | 51.7% |
| Mid cap ($2-10bn) | 26.2% |
| Small cap (<$2bn) | 19.2% |
| Developed mkts. | 97.1% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 97.1 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 9.1% | 39.9% | 17.6% | 13.5% | 3.0% | 9.3% | 8.9% | 9.0% |
| Dividend Yield | 1.2% | 2.7% | 1.3% | 0.8% | 0.5% | 0.4% | 0.3% | 0.3% |
| Total Returns | 10.3% | 42.6% | 18.9% | 14.4% | 3.5% | 9.6% | 9.2% | 9.3% | Ann. Volatility | 19.2% | 19.1% | 20.7% | 20.1% | 22.5% | 24.8% | 25.5% | 25.3% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.67 | 19% |
| MSCI EAFE | 0.64 | 27% |
| MSCI Emg Mkts | 0.30 | 13% |
Liquidity Measures
| Avg. volume (000) | 8 |
| ADV traded (mns) | $1 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.27% |
Technical Indicators
| 30d moving avg. (EMA) | $87.22 |
| Relative strength (RSI) | 64 |
| MACD/Signal | 2.65/2.36 |
| Bollinger Bands (Upper/Lower) | $95.19/$80.87 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. PBE |
Expenses vs. PBE |
ALTAR Score™ vs. PBE |
|---|---|---|---|---|
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 47.1% | -2 bp | -1.2% |
| BBH | VanEck Biotech ETF | 39.5% | -23 bp | +1.9% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 38.1% | -39 bp | -2.6% |
| IBB | iShares Biotechnology ETF | 37.9% | -13 bp | -3.4% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 31.7% | +2 bp | +4.2% |
| BBP | Virtus LifeSci Biotech Products ETF | 28.9% | +21 bp | -6.4% |
| BMED | Future Health ETF | 25.1% | +27 bp | -1.8% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 23.4% | -23 bp | -6.4% |
| GNOM | Global X Genomics & Biotechnology ETF | 22.9% | -8 bp | -5.5% |
| PJP | Invesco Pharmaceuticals ETF | 20.3% | -1 bp | +4.6% |
Risk and Returns: PBE vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/16/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
2.8%
ALTAR SCORE™
12nd
PERCENTILE
AVOID
ETFRC RATING
There are 1,399 funds in the US Equity category with an average
ALTAR Score™ of 5.4% and a standard deviation
of 2.1%. PBE's ALTAR Score™ is approximately -1.2 standard
deviations above the category average. This places PBE in the 12nd percentile
among funds in the category.
Sell-Side Consensus
$103.15
PRICE TARGET
+15.2%
UPSIDE